As February 2026 begins, U.S. stock markets have shown a strong start with major indexes like the Dow Jones and S&P 500 posting significant gains. This positive momentum sets an intriguing backdrop for investors exploring various segments of the market, including penny stocks. Although often seen as a relic from past trading eras, penny stocks—typically representing smaller or newer companies—continue to offer potential growth opportunities when backed by robust financial health. In this article, we will explore three such promising penny stocks that combine financial strength with potential for notable returns.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
Dingdong (Cayman) (DDL)	$2.89	$619.34M	✅ 3 ⚠️ 1 View Analysis >
Waterdrop (WDH)	$1.77	$640.14M	✅ 4 ⚠️ 0 View Analysis >
LexinFintech Holdings (LX)	$2.76	$464.41M	✅ 4 ⚠️ 1 View Analysis >
Global Self Storage (SELF)	$4.99	$56.58M	✅ 3 ⚠️ 3 View Analysis >
Information Services Group (III)	$3.11	$226.97M	✅ 4 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Cricut (CRCT)	$4.69	$993.08M	✅ 2 ⚠️ 2 View Analysis >
Nephros (NEPH)	$4.10	$43.57M	✅ 3 ⚠️ 2 View Analysis >
Lifetime Brands (LCUT)	$3.42	$77.48M	✅ 3 ⚠️ 2 View Analysis >
Marine Petroleum Trust (MARP.S)	$4.38	$8.76M	✅ 2 ⚠️ 3 View Analysis >

Underneath we present a selection of stocks filtered out by our screen.

Cerus (CERS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cerus Corporation is a biomedical products company with a market cap of $430.28 million.

Operations: The company generates revenue primarily from its Blood Safety segment, which accounts for $199.19 million.

Market Cap: $430.28M

Cerus Corporation, while unprofitable, has a positive cash flow and a sufficient cash runway for over three years. The company has reduced its losses by 23.9% annually over the past five years and maintains satisfactory debt levels with short-term assets exceeding liabilities. Recent developments include preliminary product revenue of US$206.1 million in 2025, marking a 14% increase from the previous year, driven by strong growth in their INTERCEPT Fibrinogen Complex line. A new agreement with Blood Centers of America aims to enhance distribution and adoption of Cerus's pathogen reduction technologies across member centers.

Seer (SEER)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Seer, Inc. is a life sciences company focused on developing and commercializing products to decode the biology of the proteome, with a market cap of approximately $113.63 million.

Operations: The company generates revenue from its Biotechnology (Startups) segment, amounting to $16.38 million.

Market Cap: $113.63M

Seer, Inc. is a life sciences company with a market cap of US$113.63 million, generating US$16.38 million in revenue from its Biotechnology segment. Despite being unprofitable with a negative return on equity of -29.19%, Seer remains debt-free and has sufficient cash runway for over three years based on current free cash flow trends. The management team and board are experienced, with average tenures exceeding industry norms, though recent insider selling raises concerns about internal confidence. A recent study published in Nature Genetics highlighted the importance of Seer's Proteograph® Product Suite for accurate proteogenomics research, enhancing its scientific credibility despite financial challenges.

Liquidmetal Technologies (LQMT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Liquidmetal Technologies, Inc. is a materials technology company that designs, develops, and sells custom products and parts made from bulk amorphous alloys to various industries globally, with a market cap of approximately $100.25 million.

Operations: The company generates revenue of $0.74 million from developing and manufacturing products and applications using amorphous alloys.

Market Cap: $100.25M

Liquidmetal Technologies, Inc., with a market cap of approximately US$100.25 million, operates as a pre-revenue company generating just US$0.74 million from its amorphous alloys products. Despite its unprofitability and negative return on equity of -7.72%, the company has managed to reduce losses by 13.6% annually over the past five years and remains debt-free with no long-term liabilities. It boasts sufficient cash runway for more than three years, supported by short-term assets of US$14.9 million exceeding liabilities significantly, although its share price has been highly volatile recently and weekly volatility remains elevated compared to most U.S stocks.

Seize The Opportunity

• Unlock our comprehensive list of 345 US Penny Stocks by clicking here.
• Want To Explore Some Alternatives? Trump's oil boom is here — pipelines are primed to profit. Discover the 21 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.